Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Francois, Doz"'
Autor:
Chris Jones, Karin Straathof, Maryam Fouladi, Darren Hargrave, Michael Prados, Adam Resnick, Francois Doz, David T.W. Jones, Sabine Mueller
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Clinical outcomes for many childhood brain tumours remain poor, despite our increasing understanding of the underlying disease biology. Advances in molecular diagnostics have refined our ability to classify tumour types and subtypes, and efforts are
Externí odkaz:
https://doaj.org/article/9f9a28d90ef94001ad056ef8b69fd052
Autor:
Francois Doz
Publikováno v:
Oncología, Vol 8, Iss 3 (2019)
Los tumores cerebrales del niño representan la primera causa de tumor sólido en pediatría y, gracias a los progresos efectuados en el tratamiento de las hemopatías malignas, ellos son actualmente la primera causa de mortalidad por cáncer en esta
Externí odkaz:
https://doaj.org/article/fc36df2892ce4ac48435d1c491127834
Publikováno v:
Oncología, Vol 8, Iss 3 (2019)
Es el tumor más frecuente del niño. Su incidencia es de 1 x 20,000 nacimientos, 2/3 de la forma son unilaterales y la edad promedio del diagnóstico es de dos años. Tiene una historia genética bastante conocida en la que la anomalía se establece
Externí odkaz:
https://doaj.org/article/f13c5c67170c4b5aa150f1e640483609
Autor:
Mathilde Chevignard, Kim S Bull, James Holt, Bertie Harrington, Jemma Castle, Marie-Amelie Heng, Colin Kennedy, Francois Doz, Birgitta Lannering, Stefan Rutkowski, Maura Massimino, Simon Bailey, Adeoye Oyefiade, Donald Mabbott, Steven C Clifford†, Debbie Hicks†
Publikováno v:
Neuro-Oncology. 24:i139-i140
Determinants of survivorship outcomes are emerging from limited studies of medulloblastoma (MB) survivors. We undertook an integrated analysis of biological (tumour group, host genetics) and clinico-demographic features in patients treated on the SIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f2dac7c46b4ea55ca8647504b10ca37
https://doi.org/10.1093/neuonc/noac079.511
https://doi.org/10.1093/neuonc/noac079.511
The outcome for children with cancer has shown enormous improvement since the first edition of this book was published in 1975. In economically privileged countries, overall survival rates have now reached 80% at five years from diagnosis, and most o
Autor:
Yassine Bouchoucha, Arnault Tauziède-Espariat, Arnaud Gauthier, Delphine Guillemot, Dorian Bochaton, Julien Vibert, Matthieur Carton, Sarah Watson, Sandrine Grossetete, Chloé Quignot, Daniel Orbach, Nadège Corradini, Gudrun Schleiermacher, Franck Bourdeaut, Marie Simbozel, Christelle Dufour, Veronique Minard, Mehdi Brahmi, Franck Tirode, Daniel Pissaloux, Marie Karanian, Marie-Christine Machet, Julien Masliah-Planchon, Olivier Delattre, Liesbeth Cardoen, Gaelle Pierron, Francois Doz
Publikováno v:
Neuro-Oncology. 24:i49-i49
BCOR-ITD tumours form an emerging family of aggressive entities with an internal tandem duplication (ITD) in the last exon of the BCOR gene. The family includes cerebral tumours, termed central nervous system BCOR-ITD (CNS BCOR-ITD), and sarcomatous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::201895c4156e462cd5f6328b28ca9601
https://doi.org/10.1093/neuonc/noac079.181
https://doi.org/10.1093/neuonc/noac079.181
Autor:
Arnault Tauziède-Espariat, Léa Guerrini-Rousseau, Alexandre Perrier, Jacob Torrejon, Flavia Bernardi, Mathilde Filser, Pascale Varlet, Emilie De Carli, Anne Pagnier, Pierre Leblond, Cécile Faure-Conter, Francois Doz, Anne-Isabelle Bertozzi, Ludovic Mansuy, Marjolaine Willems, Gilles Palenzuela, Natacha Entz-Werle, Christine Bourneix, Lauren Hasty, Olivier Delattre, Thomas Blauwblomme, Kevin Beccaria, Alice Metais, Olivier Ayrault, Fabrice Chrétien, Franck Bourdeaut, Christelle Dufour, Julien Masliah-Planchon
Publikováno v:
Neuro-Oncology. 24:i126-i126
Medulloblastoma (MB), the most frequent embryonic tumor of the cerebellum is classified into four molecular subgroups (WNT group, SHH group, group 3 and group 4). Although the vast majority of MB are sporadic, predisposing genetic diseases have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36eaaff167e04c1bea34f4b9f44c084e
https://doi.org/10.1093/neuonc/noac079.458
https://doi.org/10.1093/neuonc/noac079.458
Autor:
Sébastien Perreault, Alexander E. Drilon, Ulrik Niels Lassen, Birgit Geoerger, Karsten Nysom, Ingrid Øra, Igor T. Gavrilovic, Ricarda Norenberg, Marc Mardoche Fellous, Esther A. De La Cuesta, Theodore Willis Laetsch, Francois Doz, Cornelis Martinus van Tilburg
Publikováno v:
Journal of Clinical Oncology. 40:2010-2010
2010 Background: Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions are known oncogenic drivers in a variety of tumor types. Larotrectinib is a highly selective, CNS-active TRK inhibitor that demonstrated an objective response rate (ORR) of 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8174bb6e2224e70cebf3a881cca115f
https://doi.org/10.1200/jco.2022.40.16_suppl.2010
https://doi.org/10.1200/jco.2022.40.16_suppl.2010
Autor:
Shivaani Kummar, Lin Shen, Cornelis Martinus van Tilburg, Daniel S.W. Tan, Francois Doz, Raymond S. McDermott, C. Michel Zwaan, Karen N. Keating, Costel Chirila, Ricarda Norenberg, Marc Mardoche Fellous, Nicoletta Brega, Rui-hua Xu, Theodore Willis Laetsch, Alexander E. Drilon, David S. Hong
Publikováno v:
Journal of Clinical Oncology. 40:6563-6563
6563 Background: NTRK gene fusions have been identified as oncogenic drivers in patients (pts) with TRK fusion cancer across multiple solid tumors. Larotrectinib, a highly selective, CNS-active TRK inhibitor has shown high response rates, durable dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49a1ece2d28897171681fd4d07c731bf
https://doi.org/10.1200/jco.2022.40.16_suppl.6563
https://doi.org/10.1200/jco.2022.40.16_suppl.6563
Autor:
Daniel B Landi, David S. Ziegler, Andrea Flynn Franson, Patricia Ann Baxter, Sarah Leary, Valérie Larouche, Angela Jae Waanders, Jasper Van der Lugt, Geoffrey Brian McCowage, Francois Doz, Nada Jabado, Elisabetta Schiavello, Michal Zapotocky, Izzy Cornelio, Samuel C Blackman, Daniel Da Costa, Michael Craig Cox, Olaf Witt, Lindsay Baker Kilburn, Jordan R. Hansford
Publikováno v:
Journal of Clinical Oncology. 40:TPS10062-TPS10062
TPS10062 Background: RAF gene fusions ( BRAF and RAF1) and BRAF V600E mutations are oncogenic drivers found on a mutually exclusive basis in most pediatric low-grade gliomas (LGGs). In addition, RAF fusions ( BRAF and RAF1) have also been identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e008124ee3150bd43a94227604f46d
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10062
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10062